Rx Promotional Campaign Based On Individual Symptoms Gives FDA Allergic Reaction
This article was originally published in The Pink Sheet Daily
Executive Summary
Meda’s allergic rhinitis drug Astepro (azelastine) draws an FDA letter for a telephone sales script that focused on the drug’s effect on nasal congestion, which was not studied separately from its effect on other symptoms.
You may also be interested in...
Luvox CR Symptom Benefit Claims Draw DDMAC Warning
An FDA warning letter to Jazz Pharmaceuticals citing a Luvox CR (fluvoxamine maleate) patient brochure continues an agency trend of targeting efficacy claims about individual symptoms of a broader disease state
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.